User contributions
(newest | oldest) View (newer 50 | older 50) (20 | 50 | 100 | 250 | 500)
- 14:28, 15 May 2021 (diff | hist) . . (+15) . . m Multiple myeloma - historical (→Regimen variant #5, 0.4/9/40 (bolus doxorubicin & vincristine, dex 12 days/cycle in cycles 1-3) {{#subobject:20136a|Variant=1}}) (current)
- 14:27, 15 May 2021 (diff | hist) . . (+16) . . m Multiple myeloma, consolidation and maintenance
- 14:27, 15 May 2021 (diff | hist) . . (+68) . . m Multiple myeloma, induction (current)
- 14:25, 15 May 2021 (diff | hist) . . (-4) . . m Burkitt lymphoma (→Untreated) (current)
- 11:50, 15 May 2021 (diff | hist) . . (+11) . . m Drug index (→Interesting and Helpful Links) (current)
- 11:49, 15 May 2021 (diff | hist) . . (-94) . . m Tutorial (→Interesting and helpful links) (current)
- 09:57, 15 May 2021 (diff | hist) . . (+61) . . m Iptacopan (LNP023) (current)
- 09:51, 15 May 2021 (diff | hist) . . (+118) . . m Iptacopan (LNP023)
- 09:48, 15 May 2021 (diff | hist) . . (+30) . . m Pancreatic cancer (→Gemcitabine monotherapy {{#subobject:4f0be9|Regimen=1}})
- 09:47, 15 May 2021 (diff | hist) . . (-1,598) . . m Pancreatic cancer (→FLEC {{#subobject:a6c123|Regimen=1}})
- 09:47, 15 May 2021 (diff | hist) . . (+1,678) . . m Pancreatic cancer - historical (→Metastatic disease, first-line) (current)
- 09:46, 15 May 2021 (diff | hist) . . (+30) . . m Pancreatic cancer (→Regimen variant #2, 1000 mg/m2, 8-week lead-in ("Burris regimen") {{#subobject:5d6dd0|Variant=1}})
- 09:45, 15 May 2021 (diff | hist) . . (-1,894) . . m Pancreatic cancer (→PEFG {{#subobject:f0e123|Regimen=1}})
- 09:45, 15 May 2021 (diff | hist) . . (+1,944) . . m Pancreatic cancer - historical (→Metastatic disease, all lines of therapy)
- 09:42, 15 May 2021 (diff | hist) . . (+27) . . m Paroxysmal nocturnal hemoglobinuria (→Investigational agents) (current)
- 12:00, 14 May 2021 (diff | hist) . . (+1,144) . . m Prostate cancer (→References) (current)
- 11:59, 14 May 2021 (diff | hist) . . (0) . . m Prostate cancer (→ADT & Apalutamide {{#subobject:02eac3|Regimen=1}})
- 11:59, 14 May 2021 (diff | hist) . . (-1,144) . . m Prostate cancer (→References)
- 11:57, 14 May 2021 (diff | hist) . . (+1,144) . . m Prostate cancer (→References)
- 11:57, 14 May 2021 (diff | hist) . . (+147) . . m Prostate cancer (→ADT & Apalutamide {{#subobject:02eac3|Regimen=1}})
- 13:06, 13 May 2021 (diff | hist) . . (+8) . . m Breast cancer, triple negative (current)
- 11:38, 13 May 2021 (diff | hist) . . (0) . . m Ovarian cancer (→Regimen variant #3, q3wk AUC 6, q1wk 80 ("dose-dense") {{#subobject:d2604f|Variant=1}})
- 22:06, 12 May 2021 (diff | hist) . . (-6) . . m Small cell lung cancer - null regimens (→Placebo) (current)
- 22:02, 12 May 2021 (diff | hist) . . (+11) . . m Stub (→Bortezomib & Siltuximab) (current)
- 21:50, 12 May 2021 (diff | hist) . . (+35) . . m Multiple myeloma, relapsed-refractory (→Bortezomib monotherapy {{#subobject:eadacb|Regimen=1}})
- 21:39, 12 May 2021 (diff | hist) . . (0) . . m CNS carcinoma
- 21:38, 12 May 2021 (diff | hist) . . (0) . . m CNS lymphoma
- 21:35, 12 May 2021 (diff | hist) . . (+32) . . m Pancreatic NET (current)
- 20:41, 12 May 2021 (diff | hist) . . (+309) . . m Bladder cancer (→Paclitaxel & RT {{#subobject:89c0ea|Regimen=1}})
- 13:44, 12 May 2021 (diff | hist) . . (+277) . . m Pembrolizumab (Keytruda) (→Bladder cancer) (current)
- 13:43, 12 May 2021 (diff | hist) . . (+28) . . m Regimen classes (→Platinum-based regimen) (current)
- 13:41, 12 May 2021 (diff | hist) . . (+115) . . m Panitumumab (Vectibix) (→History of changes in FDA indication) (current)
- 13:36, 12 May 2021 (diff | hist) . . (+36) . . m Colon cancer - null regimens (→References) (current)
- 13:35, 12 May 2021 (diff | hist) . . (+12) . . m Colon cancer, RAS wild-type (→References) (current)
- 13:34, 12 May 2021 (diff | hist) . . (-64) . . m Panitumumab (Vectibix) (→History of changes in FDA indication)
- 12:38, 12 May 2021 (diff | hist) . . (+30) . . m Osimertinib (Tagrisso) (→History of changes in FDA indication) (current)
- 12:37, 12 May 2021 (diff | hist) . . (0) . . m Osimertinib (Tagrisso) (→History of changes in FDA indication)
- 12:35, 12 May 2021 (diff | hist) . . (-10) . . m Imatinib (Gleevec) (→Hypereosinophilic syndrome (HES)) (current)
- 08:03, 12 May 2021 (diff | hist) . . (+1,100) . . m Colon cancer (→Adjuvant therapy)
- 07:56, 12 May 2021 (diff | hist) . . (+65) . . m Pancreatic cancer (→References)
- 22:09, 11 May 2021 (diff | hist) . . (+1,981) . . m Diffuse large B-cell lymphoma
- 21:59, 11 May 2021 (diff | hist) . . (0) . . m Diffuse large B-cell lymphoma - historical
- 21:58, 11 May 2021 (diff | hist) . . (0) . . m Diffuse large B-cell lymphoma
- 21:43, 11 May 2021 (diff | hist) . . (+1,669) . . m Gastric cancer (→Cisplatin & Fluorouracil (CF) {{#subobject:4d9936|Regimen=1}})
- 17:07, 11 May 2021 (diff | hist) . . (+60) . . m Gefitinib (Iressa) (→History of changes in FDA indication) (current)
- 17:05, 11 May 2021 (diff | hist) . . (+67) . . m Non-small cell lung cancer (→Gefitinib monotherapy {{#subobject:ebbf2d|Regimen=1}})
- 17:03, 11 May 2021 (diff | hist) . . (-232) . . m Non-small cell lung cancer (→Regimen variant #1, 5/200 {{#subobject:5g4ff1|Variant=1}})
- 16:59, 11 May 2021 (diff | hist) . . (+60) . . m Non-small cell lung cancer, EGFR-mutated (→Regimen {{#subobject:604e4f|Variant=1}}) (current)
- 16:54, 11 May 2021 (diff | hist) . . (-7) . . m Everolimus (Afinitor) (→History of changes in FDA indication) (current)
- 16:53, 11 May 2021 (diff | hist) . . (+44) . . m Erlotinib (Tarceva) (→History of changes in FDA indication) (current)
(newest | oldest) View (newer 50 | older 50) (20 | 50 | 100 | 250 | 500)
